We are live on ! Find out more
AERI

Aerie Pharmaceuticals
AERI

Delisted

AERI was delisted on the 18th of November, 2022.

Back to rankings

176 hedge funds and large institutions have $2.96B invested in Aerie Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 75 increasing their positions, 45 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 45

66% more call options, than puts

Call options by funds: $26.2M | Put options by funds: $15.8M

4% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 25

1% more funds holding

Funds holding: 175 → 176 (+1)

0% more capital invested

Capital invested by funds: $2.94B → $2.96B (+$11.6M)

0% more funds holding in top 10

Funds holding in top 10: 10 → 10 (0)

Holders
176
Holders Change
+1
Holders Change %
+0.57%
% of All Funds
4.02%
Holding in Top 10
10
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.23%
New
26
Increased
75
Reduced
45
Closed
25
Calls
$26.2M
Puts
$15.8M
Net Calls
+$10.4M
Net Calls Change
+$24.3M

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$88.8M
2
DM
Deerfield Management
New York
+$67.9M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$30.8M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$28.1M
5
NHAS
Novo Holdings A/S
Denmark
+$18.1M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$42.7M
2
PHS
PFM Health Sciences
California
-$29.7M
3
PC
PointState Capital
New York
-$19M
4
HM
HealthCor Management
New York
-$18.1M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$9.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
26
OppenheimerFunds
New York
$25.4M +$5.93M +92,240 +29%
Russell Investments Group
27
Russell Investments Group
United Kingdom
$25.3M +$7.3M +113,598 +38%
NHAS
28
Novo Holdings A/S
Denmark
$25.1M +$18.1M +282,165 +223%
Neuberger Berman Group
29
Neuberger Berman Group
New York
$23.1M +$2.22M +34,500 +10%
Loomis, Sayles & Company
30
Loomis, Sayles & Company
Massachusetts
$22.8M +$4.36M +67,871 +22%
T. Rowe Price Associates
31
T. Rowe Price Associates
Maryland
$22.5M +$384K +5,974 +2%
Morgan Stanley
32
Morgan Stanley
New York
$22.5M -$6.49M -101,034 -22%
Millennium Management
33
Millennium Management
New York
$22M +$6.34M +98,576 +38%
PAMU
34
Pictet Asset Management (UK)
United Kingdom
$20.7M -$4.91M -76,391 -19%
Handelsbanken Fonder
35
Handelsbanken Fonder
Sweden
$20.3M +$1.61M +25,000 +8%
Ameriprise
36
Ameriprise
Minnesota
$20.3M +$847K +13,181 +4%
CS
37
Candriam SCA
Luxembourg
$20.1M +$13.2M +205,100 +169%
Balyasny Asset Management
38
Balyasny Asset Management
Illinois
$19.8M -$4.05M -63,059 -16%
Norges Bank
39
Norges Bank
Norway
$18.4M – – –
SPPAM
40
Summit Partners Public Asset Management
Massachusetts
$17.2M +$7.07M +110,000 +65%
RHJA
41
Rice Hall James & Associates
California
$17.1M -$430K -6,689 -2%
PIM
42
Provident Investment Management
Michigan
$16.1M +$16.8M +261,893 New
CS
43
Credit Suisse
Switzerland
$15.1M +$531K +8,263 +3%
SCM
44
Suffolk Capital Management
New York
$12.8M -$261K -4,058 -2%
Charles Schwab
45
Charles Schwab
California
$12.8M +$486K +7,554 +4%
Point72 Asset Management
46
Point72 Asset Management
Connecticut
$12.5M +$1.34M +20,880 +11%
HCMT
47
Highland Capital Management (Texas)
Texas
$11.1M +$4.69M +72,991 +68%
RPAM
48
Rhenman & Partners Asset Management
Sweden
$11.1M +$7.07M +110,000 +157%
Axa
49
Axa
France
$10.7M – – –
FAM
50
Fred Alger Management
New York
$10.4M -$968K -15,060 -8%
1
2
3 4 5

AERI Hedge Fund Activity: Q3 2018 in Review

176 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2018, worth a combined $2.96B — up 0.39% from $2.94B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new AERI positions and 25 closed out — a net gain of 1 holder — while 75 added to existing stakes and 45 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $88.8M. The largest seller was OrbiMed, cutting an estimated $42.7M.

  • 176 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2018, up from 175 in Q2 2018.
  • Funds reported $2.96B of Aerie Pharmaceuticals stock for Q3 2018, up 0.39% quarter-over-quarter.
  • 26 funds opened new Aerie Pharmaceuticals positions in Q3 2018 and 25 closed out, a net change of +1 holder.
  • The largest Aerie Pharmaceuticals buyer in Q3 2018 was Citadel Advisors, an estimated $88.8M added.
  • The largest Aerie Pharmaceuticals seller in Q3 2018 was OrbiMed, an estimated $42.7M sold.

Based on aggregated 13F filings for Q3 2018.